Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
Jeffrey S. Weber(NYU Langone Health), James Larkin(Trinity College Dublin), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Luis de la Cruz‐Merino, Andrew F. Hill(National Center for Emerging and Zoonotic Infectious Diseases), Leslie A. Fecher(University of Pennsylvania), C. Lance Cowey(Texas Oncology), Michael Schenker(Sorbonne Université), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Petr Arenberger(Charles University), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Maurice Lobo(Bristol-Myers Squibb (United States)), Jean‐Jacques Grob(Aix-Marseille Université), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Georgina V. Long(The University of Sydney), Paola Queirolo, Stéphane Dalle(Hospices Civils de Lyon), Margarita Askelson(Bristol-Myers Squibb (United States)), Michael Millward(The University of Western Australia), Helen Gogas(National and Kapodistrian University of Athens), Victoria Atkinson(Greenslopes Private Hospital), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Anna Maria Di Giacomo(University of Siena), Marcus O. Butler(University of Toronto)
Cited by 9
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k